For inquiries, contact us here.

News

2020

April 2020
Symberix Featured in Two PNAS Articles
February 2020
Symberix Co-Founder Gives Keynote Address at AACR Conference
February 2020
Symberix Featured in Nature Article
January 2020
Symberix Featured in Scientific American Article on Pharmacomicrobiomics

September 2019
Symberix Awarded $2 Million from National Institutes of Health to Support Lead Program

July 2019
Symberix Featured in Nature Reviews Article on Small Molecule Microbiome Therapeutics
June 2019
Symberix Awarded Multiple Grants to Expand Platform of Microbiome-Targeted Drugs

October 2018
Symberix Announces Non-Dilutive Funding Support for Lead Programs

July 2017
Manuscript on Human “GUSome” Published by Cell Press
June 2017
Symberix Selected to Present at Start-Up Stadium at International BIO Conference

September 2016
Symberix Scientist Presents at Immuno-Oncology Conference
September 2016
National Cancer Institute Awards Phase 1 SBIR Contract to Symberix
May 2016
Symberix Announces Addition of Kay Wagoner, PhD, Pharmaceutical R&D Expert and Icagen Founder and CEO, to its Board of Directors
March 2016
U.S. Patent and Trademark Office Issues Notice of Allowance of Patent Licensed to Symberix
March 2016
Genetic Engineering News Highlights Symberix in Microbiome Feature Article

November 2015
Symberix Awarded Multiple Grants from National Institutes of Health to Develop Proprietary Microbiome-Targeted Drugs
September 2015
Blackstone Entrepreneurs Network Selects Symberix as a Portfolio Company
June 2015
Symberix Receives Additional Carolina Kickstart Award from the North Carolina Translational and Clinical Sciences Institute at UNC-Chapel Hill
June 2015
Symberix CEO Presents at Translational Microbiome Conference
March 2015
Pharmaceutical Journal Highlights Research by UNC Professor and Founder of Symberix
March 2015
CED Life Science Conference Selects Symberix as Featured Showcase Presenter
February 2015
NC Department of Commerce Awards Grant to Symberix for Phase 1 Research